Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
BUSINESS Shionogi Nabs Global Rights to Maze’s Pompe Disease Therapy
May 13, 2024
-
BUSINESS Amgen Files Otezla for Palmoplantar Pustulosis in Japan
May 13, 2024
-
REGULATORY Apply Elective Care Scheme to Original Biologics with Biosimilars: Professor to LDP
May 10, 2024
-
BUSINESS Moderna Set to Develop Cancer Vaccines, Rare Disease Therapies in Japan: New Local Chief
May 10, 2024
-
BUSINESS Jardiance Positive in Japanese CKD Patients Too: Subgroup Analysis
May 10, 2024
-
REGULATORY Jaypirca, Prevymis Sail Through MHLW Panel Review; Avigan’s SFTS Use on Hold
May 10, 2024
-
BUSINESS Takeda’s Operating Profit Dips by More than Half in FY2023
May 10, 2024
-
BUSINESS Japan Ethical Drug Sales Down 2.4% in March: Crecon
May 10, 2024
-
BUSINESS Keytruda Best-Selling Drug in Japan for 7th Month in April: Encise
May 10, 2024
-
BUSINESS Ono CEO Calls for Full Abolition of Spillover Re-Pricing Rule
May 10, 2024
-
BUSINESS Ono Crosses 500 Billion Yen in FY2023 Sales, Forxiga Drives 9th Year of Growth
May 10, 2024
-
REGULATORY Researchers Urge Japan to Help Develop Domestic CAR-T Therapies
May 9, 2024
-
BUSINESS Chugai Launches Decentralized PI Trial for Cancer Drug Tobemstomig
May 9, 2024
-
BUSINESS Organon to Take Over Japan Rights to Migraine Drug Maxalt in July
May 9, 2024
-
BUSINESS Lilly Japan Nets 10% Sales Rise in 2023, Eyes No. 1 Growth for Protected Medicines
May 9, 2024
-
BUSINESS Lilly Files Tirzepatide for Obesity in Japan, Ties Up with Mitsubishi
May 9, 2024
-
REGULATORY Japan Needs Special Law on Medical Data to Allow Access Without Patient Consent: JPMA
May 8, 2024
-
ACADEMIA Japan to Forge National Registry for Leqembi, Test Genes to Predict Side Effects
May 8, 2024
-
REGULATORY New LDP Project Team Boots Up for Healthcare Transformation
May 8, 2024
-
BUSINESS Renalys, Japan Kidney Association Join Hands to Develop Innovative Therapies
May 8, 2024
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…